This acquisition will further strengthen Acumed’s position to deliver compelling and comprehensive solutions to address fractures and associated soft tissue injuries of the hand and wrist.
HILLSBORO, Ore. (PRWEB) June 13, 2019
Acumed, a leading manufacturer of orthopaedic surgical solutions, is pleased to announce the acquisition of a novel solution to address injury to the scapholunate ligament of the wrist. This area has been identified by surgeons as an area requiring surgical innovation to optimize patient outcomes. Purchased from Radicle Orthopaedics for an undisclosed amount, the RASL (Reduction and Association of the Scaphoid and Lunate) System was designed by Melvin Rosenwasser, MD. The RASL System has been granted 510(k) clearance from the US FDA for both the implant and the proprietary instrumentation.
This solution will complement Acumed’s robust hand and wrist portfolio, which includes numerous wrist plating options and the Acutrak 2® Headless Compression Screw. In particular, it will expand the solutions to our surgeons treating distal radius fractures that present with concomitant injury to the scapholunate ligament. “This acquisition will further strengthen Acumed’s position to deliver compelling and comprehensive solutions to address fractures and associated soft tissue injuries of the hand and wrist,” said Acumed President and CEO Sharon Wolfington. “Acumed will continue to build its portfolio to meet the unmet needs of the fellowship-trained Hand and Upper Extremity, Sports Medicine, Foot and Ankle, and Trauma surgeons. We will do this both with organic innovation and with acceleration acquisitions,” stated Jagi Gill, VP/GM of AcuVentures, a subsidiary of Acumed.
Chronic injury to the scapholunate ligament affects approximately 120,000 persons in the U.S. every year. “Scapholunate dissociation is one of the most common types of instability of the wrist. Injury to the associated ligament prevents normal motion and contributes to significant pain. One of the features of the RASL System is to provide precise targeting with the intent to afford a straightforward and reproducible solution to this clinical problem. We are excited to see Acumed deliver to the surgical community this new solution to address a vexing condition,” stated Dr. Rosenwasser.
Acumed is a global leader in developing innovative orthopaedic and medical solutions to improve patient care. Acumed has three decades of experience in the orthopaedic industry, with the mission of aiding the afflicted through the ingenuity of our minds, the labor of our hands, and the compassion of our hearts. Founded in 1988, Acumed is headquartered in Hillsboro, Oregon, with offices and a distribution network around the world. For more information, visit http://www.acumed.net.